Abstract
PPARs, most notably PPAR-
PPARs, most notably PPAR-
C. K. Glass and S. Ogawa, “Combinatorial roles of nuclear receptors in inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 1, pp. 44–55, 2006.
View at: Publisher Site | Google ScholarR. M. Touyz and E. L. Schiffrin, “Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications,” Vascular Pharmacology, vol. 45, no. 1, pp. 19–28, 2006.
View at: Publisher Site | Google ScholarF. Gizard, C. Amant, O. Barbier et al., “PPAR inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor ,” Journal of Clinical Investigation, vol. 115, no. 11, pp. 3228–3238, 2005.
View at: Publisher Site | Google ScholarQ. N. Diep, F. Amiri, R. M. Touyz et al., “PPAR activator effects on Ang II-induced vascular oxidative stress and inflammation,” Hypertension, vol. 40, no. 6, pp. 866–871, 2002.
View at: Publisher Site | Google ScholarA. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor- in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006.
View at: Publisher Site | Google ScholarA. Sugawara, K. Takeuchi, A. Uruno et al., “Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor- in vascular smooth muscle cells,” Endocrinology, vol. 142, no. 7, pp. 3125–3134, 2001.
View at: Publisher Site | Google ScholarM. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund, “PPAR agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice,” Hypertension, vol. 43, no. 3, pp. 661–666, 2004.
View at: Publisher Site | Google ScholarH. P. Koeffler, “Peroxisome proliferator-activated receptor and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003.
View at: Google ScholarM. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor- ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005.
View at: Publisher Site | Google ScholarC. Jiang, A. T. Ting, and B. Seed, “PPAR- agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
View at: Publisher Site | Google ScholarM. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
View at: Publisher Site | Google ScholarT. J. Standiford, V. C. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor- as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005.
View at: Publisher Site | Google ScholarA. Nencioni, F. Grünebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, “Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor ,” Journal of Immunology, vol. 169, no. 3, pp. 1228–1235, 2002.
View at: Google ScholarJ. Padilla, K. Kaur, H. J. Cao, T. J. Smith, and R. P. Phipps, “Peroxisome proliferator activator receptor- agonists and 15-deoxy--PG induce apoptosis in normal and malignant B-lineage cells,” Journal of Immunology, vol. 165, no. 12, pp. 6941–6948, 2000.
View at: Google ScholarR. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPAR and immunoregulation: PPAR mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000.
View at: Google ScholarR. Cunard, Y. Eto, J. T. Muljadi, C. K. Glass, C. J. Kelly, and M. Ricote, “Repression of IFN- expression by peroxisome proliferator-activated receptor ,” Journal of Immunology, vol. 172, no. 12, pp. 7530–7536, 2004.
View at: Google ScholarX. Y. Yang, L. H. Wang, T. Chen et al., “Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor (PPAR) agonists. PPAR co-association with transcription factor NFAT,” Journal of Biological Chemistry, vol. 275, no. 7, pp. 4541–4544, 2000.
View at: Publisher Site | Google ScholarG. Woerly, K. Honda, M. Loyens et al., “Peroxisome proliferator-activated receptors and down-regulate allergic inflammation and eosinophil activation,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 411–421, 2003.
View at: Publisher Site | Google ScholarX. Zhang, M. C. Rodriguez-Galán, J. J. Subleski et al., “Peroxisome proliferator-activated receptor- and its ligands attenuate biologic functions of human natural killer cells,” Blood, vol. 104, no. 10, pp. 3276–3284, 2004.
View at: Publisher Site | Google ScholarH. Sugiyama, T. Nonaka, T. Kishimoto, K. Komoriya, K. Tsuji, and T. Nakahata, “Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation,” European Journal of Immunology, vol. 30, no. 12, pp. 3363–3370, 2000.
View at: Publisher Site | Google ScholarJ. Becker, C. Delayre-Orthez, N. Frossard, and F. Pons, “Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?” Fundamental & Clinical Pharmacology, vol. 20, no. 5, pp. 429–447, 2006.
View at: Publisher Site | Google ScholarC. Schachtrup, T. E. Scholzen, V. Grau et al., “L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPAR-independent expression,” The International Journal of Biochemistry & Cell Biology, vol. 36, no. 10, pp. 2042–2053, 2004.
View at: Publisher Site | Google ScholarC. Delayre-Orthez, J. Becker, I. Guenon et al., “PPAR downregulates airway inflammation induced by lipopolysaccharide in the mouse,” Respiratory Research, vol. 6, p. 91, 2005.
View at: Publisher Site | Google ScholarP. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPAR-leukotriene pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996.
View at: Publisher Site | Google ScholarR. Paumelle, C. Blanquart, O. Briand et al., “Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor- via inhibition of the protein kinase C signaling pathway,” Circulation Research, vol. 98, no. 3, pp. 361–369, 2006.
View at: Publisher Site | Google ScholarT. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPAR agonist GW0742X reduces atherosclerosis in mice,” Atherosclerosis, vol. 181, no. 1, pp. 29–37, 2005.
View at: Publisher Site | Google ScholarP. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.
View at: Publisher Site | Google ScholarG. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors and induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
View at: Publisher Site | Google ScholarL. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR,” Cell, vol. 93, no. 2, pp. 229–240, 1998.
View at: Publisher Site | Google ScholarE. D. Thomas, R. E. Ramberg, G. E. Sale, R. S. Sparkes, and D. W. Golde, “Direct evidence for a bone marrow origin of the alveolar macrophage in man,” Science, vol. 192, no. 4243, pp. 1016–1018, 1976.
View at: Publisher Site | Google ScholarP. B. Bitterman, L. E. Saltzman, S. Adelberg, V. J. Ferrans, and R. G. Crystal, “Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung,” Journal of Clinical Investigation, vol. 74, no. 2, pp. 460–469, 1984.
View at: Google ScholarA. Blusse van Oud Alblas, B. van der Linden-Schrever, and R. van Furth, “Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette-Guerin,” Journal of Experimental Medicine, vol. 154, no. 2, pp. 235–252, 1981.
View at: Publisher Site | Google ScholarA. Blusse van Oud Alblas, H. Mattie, and R. van Furth, “A quantitative evaluation of pulmonary macrophage kinetics,” Cell and Tissue Kinetics, vol. 16, no. 3, pp. 211–219, 1983.
View at: Google ScholarP. Allavena, L. Piemonti, D. Longoni et al., “IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages,” European Journal of Immunology, vol. 28, no. 1, pp. 359–369, 1998.
View at: Publisher Site | Google ScholarS.-I. Hashimoto, M. Yamada, K. Motoyoshi, and K. S. Akagawa, “Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10,” Blood, vol. 89, no. 1, pp. 315–321, 1997.
View at: Google ScholarR. A. Musson, “Human serum induces maturation of human monocytes in vitro. Changes in cytolytic activity, intracellular lysosomal enzymes, and nonspecific esterase activity,” American Journal of Pathology, vol. 111, no. 3, pp. 331–340, 1983.
View at: Google ScholarH. Tanaka, E. Abe, C. Miyaura, Y. Shiina, and T. Suda, “1,25-dihydroxyvitamin induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages but not into granulocytes,” Biochemical and Biophysical Research Communications, vol. 117, no. 1, pp. 86–92, 1983.
View at: Publisher Site | Google ScholarD. W. H. Riches and M. J. Fenton, “Monocytes, macrophages, and dendritic cells of the lung,” in Murray and Nadel's Textbook of Respiratory Medicine, R. J. Mason, J. F. Murray, V. C. Broaddus, and J. A. Nadel, Eds., Elsevier Saunders, Philadelphia, Pa, USA, 4th edition, 2005.
View at: Google ScholarS. Akira, “TLR signaling,” Current topics in Microbiology and Immunology, vol. 311, pp. 1–16, 2006.
View at: Google ScholarH. Y. Reynolds, J. P. Atkinson, H. H. Newball, and M. M. Frank, “Receptors for immunoglobulin and complement on human alveolar macrophages,” Journal of Immunology, vol. 114, no. 6, pp. 1813–1819, 1975.
View at: Google ScholarZ. C. Chroneos, R. Abdolrasulnia, J. A. Whitsett, W. R. Rice, and V. L. Shepherd, “Purification of a cell-surface receptor for surfactant protein A,” Journal of Biological Chemistry, vol. 271, no. 27, pp. 16375–16383, 1996.
View at: Publisher Site | Google ScholarU. Holmskov, P. Lawson, B. Teisner et al., “Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule,” Journal of Biological Chemistry, vol. 272, no. 21, pp. 13743–13749, 1997.
View at: Publisher Site | Google ScholarA. J. Tenner, S. L. Robinson, and R. A. B. Ezekowitz, “Mannose binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126,000 component of the C1q receptor,” Immunity, vol. 3, no. 4, pp. 485–493, 1995.
View at: Publisher Site | Google ScholarA. Palecanda and L. Kobzik, “Receptors for unopsonized particles: the role of alveolar macrophage scavenger receptors,” Current Molecular Medicine, vol. 1, no. 5, pp. 589–595, 2001.
View at: Publisher Site | Google ScholarN. Khalil, O. Bereznay, M. Sporn, and A. H. Greenberg, “Macrophage production of transforming growth factor and fibroblast collagen synthesis in chronic pulmonary inflammation,” Journal of Experimental Medicine, vol. 170, no. 3, pp. 727–737, 1989.
View at: Publisher Site | Google ScholarS.-T. Uh, Y. Inoue, T. E. King Jr., E. D. Chan, L. S. Newman, and D. W. H. Riches, “Morphometric analysis of insulin-like growth factor-1 localization in lung tissues of patients with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, part 1, pp. 1626–1635, 1998.
View at: Google ScholarE. J. Campbell, J. D. Cury, C. J. Lazarus, and H. G. Welgus, “Monocyte procollagenase and tissue inhibitor of metalloproteinases. Identification, characterization, and regulation of secretion,” Journal of Biological Chemistry, vol. 262, no. 33, pp. 15862–15868, 1987.
View at: Google ScholarJ. H. Fisher, V. Sheftelyevich, Y.-S. Ho et al., “Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice,” American Journal of Physiology, vol. 278, no. 2, pp. L365–L373, 2000.
View at: Google ScholarA. H. Jobe and M. Ikegami, “Surfactant metabolism,” Clinics in Perinatology, vol. 20, no. 4, pp. 683–696, 1993.
View at: Google ScholarE. D. Rider, M. Ikegami, and A. H. Jobe, “Localization of alveolar surfactant clearance in rabbit lung cells,” American Journal of Physiology, vol. 263, no. 2, part 1, pp. L201–L209, 1992.
View at: Google ScholarT. R. Martin, G. Raugi, T. L. Merritt, and W. R. Henderson Jr., “Relative contribution of leukotriene to the neutrophil chemotactic activity produced by the resident human alveolar macrophage,” Journal of Clinical Investigation, vol. 80, no. 4, pp. 1114–1124, 1987.
View at: Google ScholarP. C. Carré, R. L. Mortenson, T. E. King Jr., P. W. Noble, C. L. Sable, and D. W. H. Riches, “Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis,” Journal of Clinical Investigation, vol. 88, no. 6, pp. 1802–1810, 1991.
View at: Google ScholarR. E. Smith, R. M. Strieter, K. Zhang et al., “A role for C-C chemokines in fibrotic lung disease,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 782–787, 1995.
View at: Google ScholarT. J. Standiford, M. W. Rolfe, S. L. Kunkel et al., “Macrophage inflammatory protein-1 expression in interstitial lung disease,” Journal of Immunology, vol. 151, no. 5, pp. 2852–2863, 1993.
View at: Google ScholarT. Thepen, G. Kraal, and P. G. Holt, “The role of alveolar macrophages in regulation of lung inflammation,” Annals of the New York Academy of Sciences, vol. 725, no. 1, pp. 200–206, 1994.
View at: Publisher Site | Google ScholarP. G. Holt, J. Oliver, N. Bilyk et al., “Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages,” Journal of Experimental Medicine, vol. 177, no. 2, pp. 397–407, 1993.
View at: Publisher Site | Google ScholarT. Kawabe, K.-I. Isobe, Y. Hasegawa, I. Nakashima, and K. Shimokata, “Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages,” Immunology, vol. 76, no. 1, pp. 72–78, 1992.
View at: Google ScholarM. D. Roth and S. H. Golub, “Human pulmonary macrophages utilize prostaglandins and transforming growth factor to suppress lymphocyte activation,” Journal of Leukocyte Biology, vol. 53, no. 4, pp. 366–371, 1993.
View at: Google ScholarS. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003.
View at: Publisher Site | Google ScholarA. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.
View at: Publisher Site | Google ScholarK. Takabayshi, M. Corr, T. Hayashi et al., “Induction of a homeostatic circuit in lung tissue by microbial compounds,” Immunity, vol. 24, no. 4, pp. 475–487, 2006.
View at: Publisher Site | Google ScholarM. R. Sartippour and G. Renier, “Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose: role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 1, pp. 104–110, 2000.
View at: Google ScholarE. Teissier, A. Nohara, G. Chinetti et al., “Peroxisome proliferator-activated receptor induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR- activation properties,” Circulation Research, vol. 95, no. 12, pp. 1174–1182, 2004.
View at: Publisher Site | Google ScholarC.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPAR,” Science, vol. 302, no. 5644, pp. 453–457, 2003.
View at: Publisher Site | Google ScholarJ. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003.
View at: Publisher Site | Google ScholarC. Wolfrum, C. M. Borrmann, T. Börchers, and F. Spener, “Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors - and -mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2323–2328, 2001.
View at: Publisher Site | Google ScholarK. Asada, S. Sasaki, T. Suda, K. Chida, and H. Nakamura, “Antiinflammatory roles of peroxisome proliferator-activated receptor in human alveolar macrophages,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 2, pp. 195–200, 2004.
View at: Publisher Site | Google ScholarR. C. Reddy, V. G. Keshamouni, S. H. Jaigirdar et al., “Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor- ligands,” American Journal of Physiology, vol. 286, no. 3, pp. L613–L619, 2004.
View at: Google ScholarA. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR- dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001.
View at: Publisher Site | Google ScholarK. J. Moore, E. D. Rosen, M. L. Fitzgerald et al., “The role of PPAR- in macrophage differentiation and cholesterol uptake,” Nature Medicine, vol. 7, no. 1, pp. 41–47, 2001.
View at: Publisher Site | Google ScholarL. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy--PG and the ligation of PPAR,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003.
View at: Publisher Site | Google ScholarY. Urade, M. Ujihara, Y. Horiguchi, K. Ikai, and O. Hayaishi, “The major source of endogenous prostaglandin production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues,” Journal of Immunology, vol. 143, no. 9, pp. 2982–2989, 1989.
View at: Google ScholarM. Alaoui-El-Azher, Y. Wu, N. Havet, A. Israël, A. Lilienbaum, and L. Touqui, “Arachidonic acid differentially affects basal and lipopolysaccharide-induced sPL-IIA expression in alveolar macrophages through NF-B and PPAR--dependent pathways,” Molecular Pharmacology, vol. 61, no. 4, pp. 786–794, 2002.
View at: Publisher Site | Google ScholarX. Lian, C. Yan, Y. Qin, L. Knox, T. Li, and H. Du, “Neutral lipids and peroxisome proliterator-activated receptor- control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice,” American Journal of Pathology, vol. 167, no. 3, pp. 813–821, 2005.
View at: Google ScholarJ. T. Huang, J. S. Welch, M. Ricote et al., “Interleukin-4-dependent production of PPAR- ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999.
View at: Publisher Site | Google ScholarP. R. S. Baker, Y. Lin, F. J. Schopfer et al., “Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42464–42475, 2005.
View at: Publisher Site | Google ScholarT. Cui, F. J. Schopfer, J. Zhang et al., “Nitrated fatty acids: endogenous anti-inflammatory signaling mediators,” Journal of Biological Chemistry, vol. 281, no. 47, pp. 35686–35698, 2006.
View at: Publisher Site | Google ScholarC. Yan and H. Du, “Alveolus formation: what have we learned from genetic studies?” Journal of Applied Physiology, vol. 97, no. 4, pp. 1543–1548, 2004.
View at: Publisher Site | Google ScholarC. Yan, X. Lian, Y. Li et al., “Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in mice,” American Journal of Pathology, vol. 169, no. 3, pp. 916–926, 2006.
View at: Publisher Site | Google ScholarD. A. Culver, B. P. Barna, B. Raychaudhuri et al., “Peroxisome proliferator-activated receptor activity is deficient in alveolar macrophages in pulmonary sarcoidosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 1, pp. 1–5, 2004.
View at: Publisher Site | Google ScholarA. M. Johann, A. von Knethen, D. Lindemann, and B. Brüne, “Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor- and attenuates the oxidative burst,” Cell Death and Differentiation, vol. 13, no. 9, pp. 1533–1540, 2006.
View at: Publisher Site | Google ScholarN. Singh, R. Webb, R. Adams et al., “The PPAR- activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 455–462, 2005.
View at: Publisher Site | Google ScholarS. Appel, V. Mirakaj, A. Bringmann, M. M. Weck, F. Grünebach, and P. Brossart, “PPAR- agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-B pathways,” Blood, vol. 106, no. 12, pp. 3888–3894, 2005.
View at: Publisher Site | Google ScholarM. A. Jakobsen, R. K. Petersen, K. Kristiansen, M. Lange, and S. T. Lillevang, “Peroxisome proliferator-activated receptor and expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands,” Scandinavian Journal of Immunology, vol. 63, no. 5, pp. 330–337, 2006.
View at: Publisher Site | Google ScholarH. Hammad, H. J. de Heer, T. Soullié et al., “Activation of peroxisome proliferator-activated receptor- in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma,” American Journal of Pathology, vol. 164, no. 1, pp. 263–271, 2004.
View at: Google ScholarV. Angeli, H. Hammad, B. Staels, M. Capron, B. N. Lambrecht, and F. Trottein, “Peroxisome proliferator-activated receptor inhibits the migration of dendritic cells: consequences for the immune response,” Journal of Immunology, vol. 170, no. 10, pp. 5295–5301, 2003.
View at: Google ScholarE. Imamoto, N. Yoshida, K. Uchiyama et al., “Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells,” BioFactors, vol. 20, no. 1, pp. 37–47, 2004.
View at: Google ScholarJ. Arias, A. S. Alberts, P. Brindle et al., “Activation of cAMP and mitogen responsive genes relies on a common nuclear factor,” Nature, vol. 370, no. 6486, pp. 226–229, 1994.
View at: Publisher Site | Google ScholarR. P. S. Kwok, J. R. Lundblad, J. C. Chrivia et al., “Nuclear protein CBP is a coactivator for the transcription factor CREB,” Nature, vol. 370, no. 6486, pp. 223–226, 1994.
View at: Publisher Site | Google ScholarR. Eckner, T.-P. Yao, E. Oldread, and D. M. Livingston, “Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation,” Genes and Development, vol. 10, no. 19, pp. 2478–2490, 1996.
View at: Publisher Site | Google ScholarS. Bhattacharya, R. Eckner, S. Grossman et al., “Cooperation of Stat2 and p300/CBP in signalling induced by interferon-,” Nature, vol. 383, no. 6598, pp. 344–347, 1996.
View at: Publisher Site | Google ScholarA. E. Horvai, L. Xu, E. Korzus et al., “Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and P300,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 4, pp. 1074–1079, 1997.
View at: Publisher Site | Google ScholarJ. J. Zhang, U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and J. E. Darnell Jr., “Two contact regions between Stat1 and CBP/p300 in interferon signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 26, pp. 15092–15096, 1996.
View at: Publisher Site | Google ScholarN. D. Perkins, L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel, “Regulation of NF-B by cyclin-dependent kinases associated with the p300 coactivator,” Science, vol. 275, no. 5299, pp. 523–527, 1997.
View at: Publisher Site | Google ScholarV. Bocher, I. Pineda-Torra, J.-C. Fruchart, and B. Staels, “PPARs: transcription factors controlling lipid and lipoprotein metabolism,” Annals of the New York Academy of Sciences, vol. 967, pp. 7–18, 2002.
View at: Google ScholarF. Chen, M. Wang, J. P. O'Connor, M. He, T. Tripathi, and L. E. Harrison, “Phosphorylation of PPAR via active ERK1/2 leads to its physical association with p65 and inhibition of NF-,” Journal of Cellular Biochemistry, vol. 90, no. 4, pp. 732–744, 2003.
View at: Publisher Site | Google ScholarG. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000.
View at: Publisher Site | Google ScholarH. Shu, B. Wong, G. Zhou et al., “Activation of PPAR or reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 345–349, 2000.
View at: Publisher Site | Google ScholarG. Piraino, J. A. Cook, M. O'Connor et al., “Synergistic effect of peroxisome proliferator activated receptor- and liver X receptor- in the regulation of inflammation in macrophages,” Shock, vol. 26, no. 2, pp. 146–153, 2006.
View at: Publisher Site | Google ScholarJ. B. Seo, H. M. Moon, W. S. Kim et al., “Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor expression,” Molecular and Cellular Biology, vol. 24, no. 8, pp. 3430–3444, 2004.
View at: Publisher Site | Google ScholarX. Z. Ruan, J. F. Moorhead, R. Fernando, D. C. Wheeler, S. H. Powis, and Z. Varghese, “PPAR agonists protect mesangial cells from interleukin 1-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 593–600, 2003.
View at: Publisher Site | Google ScholarR. P. Baughman, A. S. Teirstein, M. A. Judson et al., “Clinical characteristics of patients in a case control study of sarcoidosis,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, part 1, pp. 1885–1889, 2001.
View at: Google ScholarG. W. Hunninghake, G. N. Bedell, D. C. Zavala, M. Monick, and M. Brady, “Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis,” American Review of Respiratory Disease, vol. 128, no. 4, pp. 634–638, 1983.
View at: Google ScholarK. Shigehara, N. Shijubo, M. Ohmichi et al., “IL-12 and IL-18 are increased and stimulate IFN- production in sarcoid lungs,” Journal of Immunology, vol. 166, no. 1, pp. 642–649, 2001.
View at: Google ScholarJ. F. Seymour and J. J. Presneill, “Pulmonary alveolar proteinosis: progress in the first 44 years,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 215–235, 2002.
View at: Publisher Site | Google ScholarD. W. Golde, M. Territo, T. N. Finley, and M. J. Cline, “Defective lung macrophages in pulmonary alveolar proteinosis,” Annals of Internal Medicine, vol. 85, no. 3, pp. 304–309, 1976.
View at: Google ScholarT. Kitamura, N. Tanaka, J. Watanabe et al., “Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor,” Journal of Experimental Medicine, vol. 190, no. 6, pp. 875–880, 1999.
View at: Publisher Site | Google ScholarN. Tanaka, J. Watanabe, T. Kitamura, Y. Yamada, S. Kanegasaki, and K. Nakata, “Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor,” FEBS Letters, vol. 442, no. 2-3, pp. 246–250, 1999.
View at: Publisher Site | Google ScholarM. S. Kavuru, E. J. Sullivan, R. Piccin, M. J. Thomassen, and J. K. Stoller, “Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4, part 1, pp. 1143–1148, 2000.
View at: Google ScholarJ. F. Seymour, J. J. Presneill, O. D. Schoch et al., “Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor patients with idiopathic acquired alveolar proteinosis,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 2, pp. 524–531, 2001.
View at: Google ScholarJ. C. Gasson, “Molecular physiology of granulocyte-macrophage colony-stimulating factor,” Blood, vol. 77, no. 6, pp. 1131–1145, 1991.
View at: Google ScholarD. Metcalf, “Cellular hematopoiesis in the twentieth century,” Seminars in Hematology, vol. 36, no. 4, supplement 7, pp. 5–12, 1999.
View at: Google ScholarN. A. Nicola and D. Metcalf, “Specificity of action of colony-stimulating factors in the differentiation of granulocytes and macrophages,” Ciba Foundation Symposium, vol. 118, pp. 7–28, 1986.
View at: Google ScholarJ. A. Huffman Reed, W. R. Rice, Z. K. Zsengellér, S. E. Wert, G. Dranoff, and J. A. Whitsett, “GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice,” American Journal of Physiology, vol. 273, no. 4, part 1, pp. L715–L725, 1997.
View at: Google ScholarK. Nakata, K. S. Akagawa, M. Fukayama, Y. Hayashi, M. Kadokura, and T. Tokunaga, “Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro,” Journal of Immunology, vol. 147, no. 4, pp. 1266–1272, 1991.
View at: Google ScholarS. Worgall, R. Singh, P. L. Leopold et al., “Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA,” Blood, vol. 93, no. 2, pp. 655–666, 1999.
View at: Google ScholarD. Krumwieh, E. Weinmann, B. Siebold, and F. R. Seiler, “Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys,” International Journal of Cell Cloning, vol. 8, 1, pp. 229–248, 1990, discussion 247–248.
View at: Google ScholarG. Dranoff, A. D. Crawford, M. Sadelain et al., “Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis,” Science, vol. 264, no. 5159, pp. 713–716, 1994.
View at: Publisher Site | Google ScholarR. Nishinakamura, A. Miyajima, P. J. Mee, V. L. J. Tybulewicz, and R. Murray, “Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions,” Blood, vol. 88, no. 7, pp. 2458–2464, 1996.
View at: Google ScholarL. Robb, C. C. Drinkwater, D. Metcalf et al., “Hematopoietic and lung abnormalities in mice with a null mutation of the common subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 21, pp. 9565–9569, 1995.
View at: Publisher Site | Google ScholarE. Stanley, G. J. Lieschke, D. Grail et al., “Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 12, pp. 5592–5596, 1994.
View at: Publisher Site | Google ScholarT. L. Bonfield, C. F. Farver, B. P. Barna et al., “Peroxisome proliferator-activated receptor- is deficient in alveolar macrophages from patients with alveolar proteinosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 6, pp. 677–682, 2003.
View at: Publisher Site | Google ScholarM. Ditiatkovski, B.-H. Toh, and A. Bobik, “GM-CSF deficiency reduces macrophage PPAR- expression and aggravates atherosclerosis in ApoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2337–2344, 2006.
View at: Publisher Site | Google ScholarP. J. Christensen, R. E. Goodman, L. Pastoriza, B. Moore, and G. B. Toews, “Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent,” American Journal of Pathology, vol. 155, no. 5, pp. 1773–1779, 1999.
View at: Google ScholarJ. M. Kaplan, J. A. Cook, P. W. Hake, M. O'Connor, T. J. Burroughs, and B. Zingarelli, “15-deoxy--prostaglandin (15D-PG), a peroxisome proliferator activated receptor ligand, reduces tissue leukosequestration and mortality in endotoxic shock,” Shock, vol. 24, no. 1, pp. 59–65, 2005.
View at: Publisher Site | Google ScholarD. Liu, B.-X. Zeng, S.-H. Zhang et al., “Rosiglitazone, a peroxisome proliferator-activated receptor- agonist, reduces acute lung injury in endotoxemic rats,” Critical Care Medicine, vol. 33, no. 10, pp. 2309–2316, 2005.
View at: Publisher Site | Google ScholarM. Peters-Golden, “The alveolar macrophage: the forgotten cell in asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 3–7, 2004.
View at: Publisher Site | Google ScholarC. Tang, M. D. Inman, N. van Rooijen et al., “Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN--dependent mechanism,” Journal of Immunology, vol. 166, no. 3, pp. 1471–1481, 2001.
View at: Google ScholarM. Kobayashi, M. J. Thomassen, T. Rambasek et al., “An inverse relationship between peroxisome proliferator-activated receptor and allergic airway inflammation in an allergen challenge model,” Annals of Allergy, Asthma & Immunology, vol. 95, no. 5, pp. 468–473, 2005.
View at: Google Scholar